Update
$Karyopharm Therapeutics(KPTI.US$ Presentation Of Updated Long-term Safety, Efficacy Data From A Pre-specified Exploratory Subgroup Analysis Of SIENDO Study In Patients With Advanced Or Recurrent TP53 Wild-type Endometrial Cancer![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
